Vaccine Program Could Spawn Opportunities For Researchers

A report released last month by the Institute of Medicine (IOM) proposes the creation of a National Vaccine Authority (NVA) to oversee the entire process of vaccine research and development in the United States. The authority will also act as a liaison between the federal government and private industry for vaccine production. The report discusses, among other topics, the role of applied research in the development of new or improved vaccines against such diseases as tetanus and cholera both

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The report discusses, among other topics, the role of applied research in the development of new or improved vaccines against such diseases as tetanus and cholera both in the United States and internationally.

Though the report does not directly address expanded vaccine research opportunities under the proposed authority, Violaine Mitchell, the study director at IOM, says investigators may be attracted to a more directed approach.

"In terms of funding streams it might help direct attention to areas of top priority and attract new researchers there," she says. "On the other hand, so much of what science does well is allowing investigator-initiated research to explore new opportunities."

The report, entitled The Children's Vaccine Initiative: Achieving The Vision (Washington, D.C., National Academy Press, 1993), was produced by an 18-person committee whose members represent academia, industry, government, and nonprofit groups. The committee met on a regular basis between February 1992 and February 1993 ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Ron Kaufman

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo